Psyence Biomedical announces postponement of reverse stock split effective date

Psyence Biomedical (PBM) announced that it has decided to postpone the previously announced effective date of its reverse stock split of its issued and outstanding shares of common stock. As previously disclosed, the Company’s Board of Directors approved a reverse stock split at a ratio of 1-for-6.25, which was intended to become effective at the opening of the market on January 20, 2026. Following further internal consideration, the Company has elected to delay the effectiveness of the reverse stock split to a later date.